Researchers are edging closer to a therapy for Angelman syndrome that involves injecting molecules that can edit genes into the fetal brain. They have already succeeded in mice and say the approach could eventually treat people with the syndrome.
The work is of high interest because a similar strategy could also work for other genetic conditions linked to autism.
But the prospect of injecting molecules into fetal brains poses ethical questions, experts caution.
For the first time, researchers at University of California San Diego School of Medicine and Imperial College London, with international collaborators, have determined that Kawasaki disease (KD) can be accurately diagnosed on the basis of the pattern of host gene expression in whole blood. The finding could lead to a diagnostic blood test to distinguish KD from other infectious and inflammatory conditions.
Results of the international study published on August 6 in JAMA Pediatrics.
Kawasaki disease is the most common acquired heart disease in children. Untreated, roughly one-quarter of children with KD develop coronary artery aneurysms — balloon-like bulges of heart vessels — that may ultimately result in heart attacks, congestive heart failure or sudden death.
Transparent mice and human organs have been created by scientists using a new technique which reveals the underlying structure of tissue.
Scientists led by Dr Ali Erturk at Ludwig Maximilians University in Munich developed a process which uses organic solvents to strip away fats and pigments but preserves the structure of the cells beneath.
The new technology allows body parts to be scanned by lasers under a microscope to capture the entire structure including all the intricate blood vessels and every single cell in its specific location.
Burdening occurrence of dengue fever across the Asia-Pacific region has prompted the demand for effective vaccines and medications to supress this viral malaise. While several pharmaceutical companies are striving to develop a cure for dengue, the fever’s incidence rate in Asia-Pacific is rising at an alarming rate. A recent report published by Future Market Insights predicts that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific. Through 2027, the region will continue to be the largest market for dengue vaccines, procuring a majority revenue share and projecting revenue growth at a 17.4% CAGR.
Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1763
Future Market Insights also observes Latin America as the second-largest market for dengue vaccines, and is expected to rake in US$ 288.7 Mn towards the end of 2027. The report, titled “Dengue Vaccines Market: Global Industry Analysis and Opportunity Assessment, 2017–2027,” expects that more and more pharmaceutical giants from across the globe will be partaking in the market’s growth in the years to come. Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.
University of Arkansas astrophysicists have taken an important step toward solving the mystery of how disk galaxies maintain the shape of their spiral arms. Their findings support the theory that these arms are created by a wave of denser matter that creates the spiral pattern as it travels across the galaxy.
“The structure of spiral arms in disk galaxies is a mystery,” said Ryan Miller, visiting assistant professor of physics. “No one knows what determines the shape of these spirals, or why they have certain numbers of arms. Our research provides a clear answer to part of that mystery.”
Disk galaxies, including the Milky Way, comprise 70 percent of known galaxies. They are characterized by their spiral-shaped arms, but astronomers are not sure how these form and maintain themselves.
Worldwide, 50 million people are living with Alzheimer’s disease and other dementias. According to the Alzheimer’s Association, every 65 seconds someone in the United States develops this disease, which causes problems with memory, thinking and behavior.
It has been more than 100 years since Alois Alzheimer, M.D., a German psychiatrist and neuropathologist, first reported the presence of senile plaques in an Alzheimer’s disease patient brain. It led to the discovery of amyloid precursor protein that produces deposits or plaques of amyloid fragments in the brain, the suspected culprit of Alzheimer’s disease. Since then, amyloid precursor protein has been extensively studied because of its association with Alzheimer’s disease. However, amyloid precursor protein distribution within and on neurons and its function in these cells remain unclear.
A team of neuroscientists led by Florida Atlantic University’s Brain Institute sought to answer a fundamental question in their quest to combat Alzheimer’s disease—” Is amyloid precursor protein the mastermind behind Alzheimer’s disease or is it just an accomplice?”
